Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IB/II Study of Enzalutamide With Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression

NCT02555189 is registered in ClinicalTrials.gov with Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University as lead sponsor.

NCT NCT02555189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02555189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IB/II Study of Enzalutamide With Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase
Phase 1/2
Overall status
Terminated
Start date
December 1, 2015
Completion date
September 1, 2023
Enrollment
52 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate carcinoma, metastatic prostate carcinoma, prostate carcinoma metastatic in the bone, stage iv prostate cancer ajcc v7